251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
Canada
647 479 9828
https://www.aptose.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 35
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. William G. Rice Ph.D. | Chairman, President, CEO & Chief Accounting Officer | 883.15k | N/A | 1959 |
Mr. Fletcher Payne | Senior VP, CFO, Chief Business Officer & Secretary | 637.95k | N/A | 1963 |
Dr. Rafael Bejar M.D., Ph.D. | Senior VP & Chief Medical Officer | 677.23k | N/A | 1973 |
Mr. Philippe Ledru | Senior VP & Chief Commercial Officer | 591.07k | N/A | 1968 |
Mr. Roger Davies B.Sc. | Vice President of Operations | N/A | N/A | N/A |
Dr. Marc Wiles Ph.D. | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
Mr. Brooks Ensign M.B.A. | VP & Controller | N/A | N/A | N/A |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Aptose Biosciences Inc.’s ISS Governance QualityScore as of March 1, 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 9.